@alphaclubsupps's testosterone ester claims, fact-checked

What did @alphaclubsupps actually say?

The creator ran through three common testosterone esters used in TRT: cypionate, enanthate, and Sustanon. They called cypionate "the gold standard," cited a half-life of seven to eight days, and praised its carrier oil as less viscous. They flagged enanthate as having anecdotal links to "pit problems" and said they personally avoid it. Sustanon got labeled a "cocktail of four different esters" that causes "spikes and crashes." The NHS, they argued, is slow to adopt cypionate and oddly fond of Sustanon.

The video is opinion-heavy and leans on personal experience rather than cited research. That is not automatically wrong, but it is worth separating the pharmacology claims from the preference claims, because those are two very different things.

Does the science back this up?

On the half-life claim, they are in the right ballpark. The pharmacology is broadly correct, though the "gold standard" framing is personal preference dressed up as clinical fact.

Testosterone cypionate has a reported half-life of approximately seven to eight days, which is consistent with what the creator stated. Testosterone enanthate sits at roughly four and a half to five days, making it meaningfully shorter than cypionate, not practically identical. A 2018 review by Bhasin et al. in the New England Journal of Medicine confirmed that both esters produce similar steady-state testosterone levels when dosed appropriately, but the half-life difference does have real implications for injection frequency and level stability.

Sustanon 250 contains four esters: propionate (half-life around two to three days), phenylpropionate (roughly four to five days), isocaproate (around nine days), and decanoate (approximately fourteen to sixteen days). The concern about fluctuating levels is pharmacologically plausible, particularly if Sustanon is injected infrequently, as the NHS often prescribes it. A 2014 analysis by Behre et al. in the Journal of Clinical Endocrinology and Metabolism noted that Sustanon dosed every three to four weeks produced wider peak-to-trough variation than more frequent protocols.

What did they get wrong (or right)?

They got the broad strokes right on Sustanon's complexity and cypionate's stability. But the enanthate claim is where things get sloppy.

The creator says there is "a lot of anecdotal evidence" that off-label enanthate causes "pit problems," which they do not explain further. Armpit odor complaints tied to testosterone therapy are real and discussed in patient communities, often linked to androgenic stimulation of apocrine glands. But no peer-reviewed evidence links enanthate specifically to worse body odor outcomes compared to cypionate. The esters themselves are metabolized to identical bioidentical testosterone once cleaved. Any androgenic side effects, including odor changes, are effects of testosterone itself, not the ester. Attributing "pit problems" to enanthate specifically, without clinical evidence, is misleading.

The claim that cypionate is less viscous is also worth scrutiny. Viscosity in testosterone preparations depends primarily on the carrier oil, not the ester. Cypionate is often suspended in cottonseed oil, enanthate frequently in sesame or castor oil. Viscosity differences exist between products, but they are formulation-specific, not ester-specific. The creator is conflating the ester with the carrier oil.

The NHS criticism has some legitimate grounding. UK prescribing guidelines have historically favored Sustanon over cypionate, and patient advocacy groups have raised valid concerns about infrequent Sustanon dosing protocols.

What should you actually know?

If you are on TRT or considering it, the ester debate matters less than how your protocol is structured overall. Talk to a licensed prescriber before changing anything.

Cypionate and enanthate both deliver testosterone effectively. The half-life difference is real but manageable with appropriate dosing frequency. Enanthate dosed twice weekly produces stable levels comparable to cypionate on the same schedule, per the Bhasin et al. 2018 review. Sustanon is not inherently bad, but it is genuinely harder to dose for stable levels because of the multi-ester composition, and its typical NHS prescribing schedule of every three to four weeks is considered suboptimal by most endocrinologists today.

The creator's personal preference for cypionate is fine. Framing it as a universal "gold standard" and implying enanthate causes unique side effects without clinical evidence is a step beyond what the data supports. If you are being prescribed enanthate and your levels are stable, there is no pharmacological reason to switch based on this video.